Streetbeat News

Price Targets

BLRX

HC Wainwright & Co. analyst Joseph Pantginis has reiterated a 'Buy' rating on BioLine Rx (NASDAQ:BLRX) and maintained a $19 price target.

Portfolio Pulse from richadhand@benzinga.com

August 31, 2023 | 8:17 am

IFRX

HC Wainwright & Co. analyst Edward White has reiterated a 'Buy' rating on InflaRx (NASDAQ:IFRX) and maintained a price target of $9.

Portfolio Pulse from richadhand@benzinga.com

August 31, 2023 | 8:15 am

VEEV

Piper Sandler analyst Brent Bracelin maintains an Overweight rating on Veeva Systems (VEEV) and raises the price target from $232 to $235.

Portfolio Pulse from richadhand@benzinga.com

August 31, 2023 | 8:13 am

CRM

Piper Sandler analyst Brent Bracelin maintains an Overweight rating on Salesforce (NYSE:CRM) and raises the price target from $248 to $268.

Portfolio Pulse from richadhand@benzinga.com

August 31, 2023 | 8:12 am

BIG

Loop Capital analyst Anthony Chukumba maintains a 'Hold' rating on Big Lots (NYSE:BIG) and raises the price target from $6 to $7.

Portfolio Pulse from Benzinga Newsdesk

August 30, 2023 | 7:06 pm

AMBA

Roth MKM analyst Suji Desilva has maintained a Neutral rating on Ambarella (NASDAQ:AMBA) and lowered the price target from $75 to $60.

Portfolio Pulse from Benzinga Newsdesk

August 30, 2023 | 7:03 pm

PLNT

Macquarie analyst Paul Golding maintains an Outperform rating on Planet Fitness (NYSE:PLNT) but lowers the price target from $85 to $77.

Portfolio Pulse from Benzinga Newsdesk

August 30, 2023 | 7:01 pm

BBY

DA Davidson analyst Michael Baker maintains a 'Buy' rating on Best Buy Co (NYSE:BBY) and raises the price target from $87 to $90.

Portfolio Pulse from Benzinga Newsdesk

August 30, 2023 | 7:00 pm

TKR

In the last quarter, Timken (NYSE:TKR) received one somewhat bullish rating and three indifferent ratings from analysts. Over the past three months, four analysts have offered 12-month price targets for Timken, with an average price target of $95.5, up 2.41% from the previous average of $93.25.

Portfolio Pulse from Benzinga Insights

August 30, 2023 | 7:00 pm

FN

Fabrinet (NYSE:FN) has received positive analyst ratings in the last quarter, with 4 bullish and 2 somewhat bullish ratings. The average 12-month price target for the company, according to 6 analysts, is $143.0, with a high of $200.00 and a low of $28.00. This average price target has increased by 4.38% over the past month.

Portfolio Pulse from Benzinga Insights

August 30, 2023 | 7:00 pm